News | Oncology Diagnostics | September 18, 2015

EM Imaging Obtains Global License for Early-Stage Colorectal Cancer Detection Agent

Optical imaging agent improves detection of pre-cancerous polyps by 25 percent over colonoscopy

EMI-137, optical imaging agent, detection, early stage, colorectal cancer
system, trial, EMI-137, colorectal cancer, optical imaging agent

System used during the EMI-137 trial

September 18, 2015 — Edinburgh Molecular Imaging Ltd. (EM Imaging) has signed an exclusive global license for a novel optical imaging agent that could improve the detection of early-stage colorectal cancer.

EM Imaging recently signed the licensing agreement with GE Healthcare Ltd. The company will now complete the development of the imaging agent “EMI-137” that can help doctors identify colorectal cancer early.

In a recent scientific study, reported in the scientific journal Nature Medicine, the EMI-137 agent allowed doctors to see more early-stage colorectal cancer (CRC) and precancerous tumors, which can then easily be removed via colonoscopy.  However, screening with a colonoscope, which is currently the most common method, can miss up to 25 percent of precancerous growths, especially smaller, flat lesions.

James Hardwick, M.D., lead investigator on the study said, “Of the 47 precancerous polyps detected in this study, 12 were missed using a standard colonoscope. This underlines how unreliable this method can be, and we therefore welcome life-saving new technology like EMI-137. This agent has the potential to make polyps light up like light bulbs – allowing clinicians to detect and remove more polyps, prevent more cancers and save more lives.”

Evidence that colorectal cancer can be prevented by the removal of pre-cancerous lesions and polyps (abnormal growth of tissue) is strong. The EMI-137 agent can help doctors more easily identify these suspicious lesions, take a sample (biopsy) or remove the lesion completely. Colorectal cancer is the second most common cause of cancer in women and the third most common in men, and is a major cause of death. 

The Phase I/IIa study in 35 subjects (20 healthy volunteers and 15 patients with high risk of CRC) showed that optical molecular imaging using the fluorescent agent is feasible and safe.

Fluorescence colonoscopy in patients receiving intravenous EMI-137 enabled the visualization of all neoplastic polyps that were visible with white light, and additionally, detected previously missed polyps that were not visible with white light alone. This enables the detection of polyps missed by other techniques.

EMI-137 is a water-soluble compound consisting of a 26–amino acid cyclic peptide, conjugated to a fluorescent cyanine dye, that binds to human tyrosine kinase (c-Met), a receptor frequently overexpressed during cancer growth. EMI-137 has the potential on intravenous administration to image a wide range of cancers — including breast, esophageal, ovarian, thyroid, bile duct carcinoma and lung cancer — due to its specific targeting of the c-Met–receptor.

Sian Godwin, head of licensing at GE Healthcare, said, “We’re pleased EM Imaging will develop and commercialize GE-137, as optical agents can be useful in clinical and research settings for a wide range of common diseases. We see broad partnership and licensing across our research and development portfolio as a way to increase access to new technologies in precision medicine, help develop better diagnostics for patients and reduce the cost of healthcare.”

Neville Young, M.D., program manager, Colorectal Therapies Healthcare Technologies Cooperative, said, "The NIHR [National Institute for Health Research]-funded Colorectal Therapies HTC, based at the University of Leeds, drives a national network of clinicians and academics who are funded to support the development of innovative new technologies that have the potential to benefit patients affected by colorectal disease. We are excited to be working with EM Imaging to help demonstrate both the cost effectiveness and clinical efficacy of their new colorectal tumo r tagging peptide. This technology offers the possibility to identify and remove more easily any cancerous polyps in a patient undergoing a colonoscopy.”

For more information: www.edinimage.com

Related Content

Guerbet Partners With Imalogix on Dose Optimization With Artificial Intelligence
News | Radiation Dose Management | August 14, 2018
August 14, 2018 — Guerbet LLC USA announced a commercial partnership with Imalogix, a provider of...
ACR LI-RADS Steering Committee Releases New Version of CT/MRI LI-RADS
News | Clinical Decision Support | August 13, 2018
August 13, 2018 — The American College of Radiology Liver Imaging Reporting and Data System (LI-RADS) steering commit
PET Tracer Identifies Estrogen Receptor Expression Differences in Breast Cancer Patients
News | PET Imaging | August 09, 2018
In metastatic breast cancer, prognosis and treatment is largely influenced by estrogen receptor (ER) expression of the...
Metro Health-University of Michigan Health Partners With Eon to Improve Lung Cancer Care
News | Oncology Diagnostics | August 07, 2018
Metro Health-University of Michigan Health announced it is partnering with healthcare data company Eon to improve the...
Gary D. Luker Named Editor of Radiology: Imaging Cancer

Image courtesy of University of Michigan Medical School

News | Oncology Diagnostics | August 06, 2018
The Board of Directors of the Radiological Society of North America (RSNA) announced that Gary D. Luker, M.D., will...
Videos | Contrast Media | August 03, 2018
Lawrence Tanenbaum, M.D., FACR, vice president and director of advanced imaging at RadNet, discusses the latest resea
computed tomography brain scan

Image courtesy of Pixabay

News | Clinical Trials | July 19, 2018
The use of computed tomography (CT) scans has increased dramatically over the last two decades. CT scans greatly...
CT Decision Instrument Reliably Guides Pediatric Blunt Trauma imaging Decisions

This is a four-site prospective observational cohort. Image courtesy of Kirsty Challen, B.Sc., MBCHB, MRES, Ph.D., Lancashire Teaching Hospitals, United Kingdom.

News | Clinical Decision Support | July 18, 2018
A new study finds The Pediatric NEXUS Head Computed Tomography (CT) Decision Instrument (DI) reliably identifies blunt...
Study Points to Need for Performance Standards for EHR Usability and Safety
News | Electronic Medical Records (EMR) | July 18, 2018
A novel new study provides compelling evidence that the design, development and implementation of electronic health...
Artificial Intelligence Provides Faster, Clearer MRI Scans

A new artificial-intelligence-based approach to image reconstruction, called AUTOMAP, yields higher quality images from less data, reducing radiation doses for CT and PET and shortening scan times for MRI. Shown here are MR images reconstructed from the same data with conventional approaches, at left, and AUTOMAP, at right. Athinoula A. Martinos Center for Biomedical Imaging, Massachusetts General Hospital

News | Artificial Intelligence | July 17, 2018
A research team with funding from the National Institute for Biomedical Imaging and Bioengineering (NIBIB) has...
Overlay Init